NCT03129269

Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 345 (estimated)
• Sponsor: University Hospital, Toulouse · Academic / Other
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

The current study seeks to examine the prevalence of amyloid pathology, among patients referred to the Toulouse Geriatric Frailty Clinic presenting objective memory impairment. We also aim to fully characterize the clinical progression of frail cognitively impaired patients presenting AD (Alzheimer Disease) pathology vs those who also present a cognitive impairment but do not have AD pathology.

Detailed description

The COGFRAIL study is a monocentric study integrating the longitudinal follow-up of 345 individuals referred to the Toulouse Frailty Clinic during 2 years. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease. * Visits will be scheduled at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation. * At 6 and 18 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check. * PET-Scan will be scheduled in the 2 months following inclusion for amyloid measurements. The MRI will be proposed, depending on the clinical relevance * A blood sample for biobank will be taken at visit 2 and at the end of the study Extension study (CogFrail-Plus): The extension study will integrate an additional 2 years follow-up of the COGFRAIL study participants, following the initial 2 years period of the study: * 2 Visits will be scheduled at 36 and 48 months for a full neuropsychological, functional and physical evaluation * At 30 and 42 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check * A blood sample will be taken at 36 and 48 months.

Conditions

• Frail Elderly

Interventions

Type	Name	Description
PROCEDURE	MRI and PET scan	Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.

Timeline

• Start date: 2017-01-02
• Primary completion: 2026-01-02
• Completion: 2026-12-31
• First posted: 2017-04-26
• Last updated: 2024-02-12

Locations

1 site across 1 country: France